ProKidney (PROK) just unveiled an announcement.
ProKidney Corp. announced encouraging interim results from its REGEN-007 Phase 2 trial, showing stabilized kidney function in patients with diabetes and chronic kidney disease who received their innovative treatment, rilparencel. With no serious adverse events reported, the company is moving forward confidently, resuming manufacturing and patient screening in various global studies. They are also awaiting a key regulatory equivalence declaration to expand their European operations, highlighting their commitment to advancing kidney disease treatments amid a competitive biotech landscape.
See more insights into PROK stock on TipRanks’ Stock Analysis page.
